Non-small cell lung cancer · line 2 · Capmatinib monotherapy (GEOMETRY mono-1) — MET ex14 NSCLC

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	standard
Linked regimen	`REG-CAPMATINIB-NSCLC`

ID	`IND-NSCLC-2L-MET-AMP-CAPMATINIB`
Type	Indication
Status	reviewed 2026-04-29 \| pending_clinical_signoff
Diseases	`DIS-NSCLC`
Sources	`SRC-ESMO-NSCLC-METASTATIC-2024` `SRC-GEOMETRY-WOLF-2020` `SRC-NCCN-NSCLC-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Distinct from IND-NSCLC-2L-MET-EX14-CAPMATINIB (MET ex14 skipping, FDA label). Off-label MET-amp use supported by GEOMETRY mono-1 high-amp cohort + NCCN/ESMO 2024-2025 listing. Tepotinib alternative (separate Indication or shared with MET-amp; this chunk uses capmatinib as default per existing REG-CAPMATINIB-NSCLC reuse). Acquired-resistance context (post-osimertinib in EGFR-mut) currently routes to amivantamab + lazertinib via existing IND-NSCLC-2L-EGFR-POST-OSI-AMI-LAZ; this IND addresses primarily the de-novo MET-amp NSCLC population.

Used By

Algorithms

ALGO-NSCLC-METASTATIC-2L - ALGO-NSCLC-METASTATIC-2L